MedTech President shares thoughts, hopes for NYS Bio/Med industry.
FDA can resume using the targeted fees toward advancing its drug and medical device review program.
New timeline spells out what manufacturers can expect in terms of possible communications with FDA.
CONNECTING NEW YORK STATE’S BIO/MED INDUSTRY
MedTech boosts the success and growth of its members and the bioscience and medical technology industry in New York State through collaboration, information, education, advocacy and by trumpeting the story.
Explore our site to learn more about MedTech and to find out how to become a member organization.